S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:NAUT

Nautilus Biotechnology Stock Forecast, Price & News

$4.43
-0.06 (-1.34%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.21
$4.56
50-Day Range
$4.43
$6.04
52-Week Range
$4.21
$25.89
Volume
423,458 shs
Average Volume
441,387 shs
Market Capitalization
$550.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive NAUT News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.


About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.

Headlines

Nautilus Biotechnology (NASDAQ:NAUT) Shares Gap Down to $5.77
December 28, 2021 |  americanbankingnews.com
Nautilus Biotechnology (NASDAQ:NAUT) Shares Gap Up to $5.27
December 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
82
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.30 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$550.07 million
Optionable
Optionable

Company Calendar

Last Earnings
11/01/2021
Today
1/16/2022
Next Earnings (Estimated)
2/01/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

1059th out of 1,405 stocks

Analytical Instruments Industry

26th out of 33 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Nautilus Biotechnology (NASDAQ:NAUT) Frequently Asked Questions

Is Nautilus Biotechnology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nautilus Biotechnology stock.
View analyst ratings for Nautilus Biotechnology
or view top-rated stocks.

When is Nautilus Biotechnology's next earnings date?

Nautilus Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Nautilus Biotechnology
.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its quarterly earnings results on Monday, November, 1st. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.02.
View Nautilus Biotechnology's earnings history
.

What price target have analysts set for NAUT?

4 analysts have issued twelve-month price objectives for Nautilus Biotechnology's shares. Their forecasts range from $8.00 to $13.00. On average, they expect Nautilus Biotechnology's stock price to reach $10.33 in the next twelve months. This suggests a possible upside of 133.3% from the stock's current price.
View analysts' price targets for Nautilus Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Nautilus Biotechnology's key executives?

Nautilus Biotechnology's management team includes the following people:

What is Nautilus Biotechnology's stock symbol?

Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT."

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.01%). Company insiders that own Nautilus Biotechnology stock include Anna Mowry, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc and Sujal M Patel.
View institutional ownership trends for Nautilus Biotechnology
.

Which institutional investors are buying Nautilus Biotechnology stock?

NAUT stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Nautilus Biotechnology stock in the last two years include Anna Mowry, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, and Sujal M Patel.
View insider buying and selling activity for Nautilus Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nautilus Biotechnology's stock price today?

One share of NAUT stock can currently be purchased for approximately $4.43.

How much money does Nautilus Biotechnology make?

Nautilus Biotechnology has a market capitalization of $550.07 million.

How many employees does Nautilus Biotechnology have?

Nautilus Biotechnology employs 82 workers across the globe.

What is Nautilus Biotechnology's official website?

The official website for Nautilus Biotechnology is www.nautilus.bio.

Where are Nautilus Biotechnology's headquarters?

Nautilus Biotechnology is headquartered at 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003.

How can I contact Nautilus Biotechnology?

Nautilus Biotechnology's mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The company can be reached via phone at 206-333-2001.


This page was last updated on 1/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.